Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Egln1Tie2Cre Mice Exhibit Similar Therapeutic Responses to Sildenafil, Ambrisentan, and Treprostinil as Pulmonary Arterial Hypertension (PAH) Patients, Supporting Egln1Tie2Cre Mice as a Useful PAH Model

International Journal of Molecular Sciences(2023)10.3390/ijms24032391Source: DataRank Database

Egln1Tie2Cre Mice Exhibit Similar Therapeutic Responses to Sildenafil, Ambrisentan, and Treprostinil as Pulmonary Arterial Hypertension (PAH) Patients, Supporting Egln1Tie2Cre Mice as a Useful PAH Model is a research paper published in International Journal of Molecular Sciences (2023). On theSindex it has a DataRank of 0. It has been cited 6 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access6 citations

Download PDF

Cite:

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (4 grants)Impact (FWCI 1.00)OA: goldTopics (55)IDs (PubMed, PMC, OpenAlex)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (3)

Jingbo Dai ORCID,You‐Yang Zhao ORCID,Yi Peng ORCID

Live enrichment

PubMed:36768713 PMC:PMC9916894 OpenAlex:https://openalex.org/W4318053816

NIH

Grant: R01HL162299

NIH

Grant: R01HL133951

NIH

Grant: R01HL164014

NIH

Grant: R01HL148810

FWCI

1.00

Citation Percentile

0.7%

Citation Trend

2024

2025

2026

goldLicense: cc-by

journalhttps://www.mdpi.com/1422-0067/24/3/2391/pdf?version=1674723111

publisherhttps://www.mdpi.com/1422-0067/24/3/2391/pdf?version=1674723111

publisherhttps://www.mdpi.com/1422-0067/24/3/2391/pdf

journalhttps://doi.org/10.3390/ijms24032391

repositoryhttps://pubmed.ncbi.nlm.nih.gov/36768713

Fields of Study

Pulmonary Hypertension Research and TreatmentsRenin-Angiotensin System StudiesVascular Anomalies and TreatmentsMiceAnimalsSildenafil CitratePulmonary Arterial HypertensionVascular RemodelingHypertension, PulmonaryFamilial Primary Pulmonary HypertensionVasodilator AgentsHypoxia-Inducible Factor-Proline DioxygenasesHeart FailurePulmonary ArteryEpoprostenolPhenylpropionatesPyridazines

MeSH Terms

Sildenafil CitratePulmonary Arterial HypertensionAnimalsHeart FailureHypertension, PulmonaryPhenylpropionatesEpoprostenolPulmonary ArteryPyridazinesVasodilator AgentsMiceHypoxia-Inducible Factor-Proline DioxygenasesFamilial Primary Pulmonary HypertensionVascular Remodeling

Keywords

TreprostinilAmbrisentanSildenafilMedicinePulmonary hypertensionBosentanRight ventricular hypertrophyPharmacologyHeart failureVascular resistanceInternal medicineCardiologyVasodilationIloprostNitric oxideProstacyclinEndothelin receptorBlood pressureReceptorpulmonary vascular remodelingPulmonary Arterial HypertensionEgln1Hif Prolyl HydroxylasePulmonary Arterial Hypertension Animal Model

Sustainable Development Goals

SDG 0: Good health and well-being